Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Fulgent Genetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Fulgent Genetics's regulatory disclosures and financial reporting.
Xie Jian, President and COO of Fulgent Genetics (FLGT) reported a sale of 696 shares on 08/25/2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/23/2023. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, with a reported weighted-average price of $21.5016. After the sale, the reporting person beneficially owns 366,448 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust, of which he serves on the investment committee and for which he disclaims beneficial interest except for any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Ming Hsieh, Fulgent Genetics (FLGT) director, CEO and 10% owner, reported a withholding of 2,115 common shares on 08/23/2025 at a price of $21.77 per share to satisfy tax withholding upon vesting of restricted stock units granted on 02/23/2023. After the withholding, Mr. Hsieh directly holds 807,225 shares and retains substantial indirect holdings: 7,895,115 shares held by a Dynasty Trust, 220,816 shares held by the Ming Hsieh Trust, and two 1,000-share UTMA accounts for which he is custodian. The Form 4 was signed by an attorney-in-fact on 08/26/2025. The filing clarifies the trust relationships and voting/dispositive powers for the indirect holdings.
Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc. (FLGT) reported a routine disposition on 08/23/2025 in which 670 shares of common stock were disposed (transaction code F) at a price of $21.77 per share. The filing explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023. After the withholding, the reporting person beneficially owned 339,158 shares directly. The Form 4 is signed by Paul Kim on 08/26/2025.
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock on 08/25/2025 to satisfy tax withholding from vested restricted stock units originally granted on February 23, 2023. The Form 4 shows 548 shares sold at a weighted-average price of $21.5016 (individual sale prices ranged from $21.46 to $21.57). After the sale, the reporting person beneficially owned 959,091 shares. The filing was submitted by attorney-in-fact Paul Kim on 08/26/2025.
Form 144 notice for Fulgent Genetics, Inc. (FLGT): An individual identified as Jian Xie proposes to sell 696 shares of the issuer's common stock through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $14,965.08 and an approximate sale date of 08/25/2025 on NASDAQ. The shares were acquired on 02/23/2023 as restricted stock vesting from Fulgent Genetics as equity compensation; the filer shows total acquired amount of 14,573 shares. The issuer has 30,609,044 shares outstanding. The filer reported three prior sales in the past three months totaling 3,008 shares for gross proceeds of $61,471.47. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.
Fulgent Genetics (FLGT) Q2-25 10-Q highlights
- Revenue: $81.8 m, up 15% YoY; 1H-25 revenue $155.3 m (+15%). Precision Diagnostics remains the largest line ($47.3 m, 58%).
- Gross margin: 42.1% vs 37.3% prior-year as cost discipline in laboratory services offsets mix shift.
- Operating loss: –$19.7 m (vs –$18.9 m). Operating expenses rose 19% to $54.1 m on higher G&A (+24%) and marketing spend (+43%).
- Net loss attributable to shareholders: –$19.0 m (EPS –$0.62) vs –$8.7 m (–$0.29). 1H-25 EPS –$0.99.
- Impairment: $9.9 m write-down of Helio Genomics investment drove other expense; without it, other income was $8.1 m interest.
- Cash & investments: $777 m (cash + marketable securities) with $87.9 m cash vs $55.1 m YE-24. Long-term securities declined $86 m as durations shortened; total assets $1.2 bn.
- Operating cash flow: –$34.6 m vs +$11.6 m prior year, due mainly to $33 m federal tax payments and higher receivables.
- Share activity: Repurchased $13.9 m stock YTD; share count 30.6 m.
- Customer concentration: One institutional customer accounted for 22% of Q2 revenue and 29% of receivables.
- Regulatory matters: DOJ CIDs on lab billing and HRSA audit remain open; SEC investigation closed with no action (previous $1 m accrual reversed).
Outlook: Management did not provide forward guidance in the filing. Revenue growth persists but profitability deteriorated due to higher opex and one-time impairment; cash position remains strong.
Fulgent Genetics (FLGT) filed a Form 4 showing that CFO & Treasurer Paul Kim had 2,743 common shares withheld on 07/26/2025 to cover taxes upon the vesting of RSUs tied to the 2022 Fulgent Pharma merger. The transaction was coded “F,” meaning it was an automatic, non-discretionary share surrender for tax withholding, not an open-market sale. The shares were valued at an implied $18.37 each (company-supplied price).
After the withholding, Kim directly owns 339,828 shares, so his economic exposure fell by <1 %. No derivative securities were exercised or disposed of, and no cash changed hands. Because the disposition is routine and immaterial relative to Kim’s total stake, the filing is largely neutral for investors and does not alter the company’s fundamental outlook.